Journal: Molecular Oncology
Article Title: An in vivo genome‐wide shRNA screen identifies BCL6 as a targetable biomarker of paclitaxel resistance in breast cancer
doi: 10.1002/1878-0261.12964
Figure Lengend Snippet: BCL6i enhances paclitaxel‐induced breast cancer cell viability and tumor regression. Trypan blue exclusion assay was used to investigate the effect of paclitaxel (7.5 n m ) and/or BCL6i (50 µ m ) treatment on the number of viable MDA‐MB‐231 cells immediately after 24 h of treatment (A) and 72 h of post‐treatment termination (B) ( n = 4). (C) BCL6 expression in a panel of breast cancer cell lines is assessed by qPCR ( n = 4). (D) Trypan blue exclusion assay was used to investigate the effect of 24‐h paclitaxel (3.75 n m ) and/or BCL6i (50 µ m ) treatment on the number of viable MDA‐MB‐468 cells 72 h of post‐treatment termination. (A to D) Error bars represent standard deviation, and significance was determined using one‐way ANOVA (repeated measures) followed by Tukey’s post‐test. (E and F) The effect of intraperitoneal BCL6i and/or paclitaxel treatment (started day 18 postcell injection and ended on day 42) on MDA‐MB‐231 tumors ( n = 12) was assessed by measuring tumor volumes (E) and final tumor weights (F). Error bars represent standard error of the mean. (E) Tumor growth was modeled using simple linear regression and the slopes of the lines compared. The slopes are significantly different from each other ( P value = 0.0031). (F) Significance was determined using one‐way ANOVA followed by Tukey’s post‐test. (A to F) P values are indicated as follows: < 0.05 =*, < 0.01 =**, and < 0.001 =***. [Colour figure can be viewed at wileyonlinelibrary.com ]
Article Snippet: Viable cells were then collected and counted using Trypan Blue exclusion cell viability stain (Thermo Fisher Scientific) or continued to be cultured for another 72 h (without treatment) and then collected and counted, and viable cell numbers were calculated relative to the no‐treatment controls.
Techniques: Trypan Blue Exclusion Assay, Expressing, Standard Deviation, Injection
Bio-Rad is a verified supplier 
![BCL6i enhances paclitaxel‐induced breast cancer <t>cell</t> <t>viability</t> and tumor regression. <t>Trypan</t> <t>blue</t> <t>exclusion</t> assay was used to investigate the effect of paclitaxel (7.5 n m ) and/or BCL6i (50 µ m ) treatment on the number of viable MDA‐MB‐231 cells immediately after 24 h of treatment (A) and 72 h of post‐treatment termination (B) ( n = 4). (C) BCL6 expression in a panel of breast cancer cell lines is assessed by qPCR ( n = 4). (D) Trypan blue exclusion assay was used to investigate the effect of 24‐h paclitaxel (3.75 n m ) and/or BCL6i (50 µ m ) treatment on the number of viable MDA‐MB‐468 cells 72 h of post‐treatment termination. (A to D) Error bars represent standard deviation, and significance was determined using one‐way ANOVA (repeated measures) followed by Tukey’s post‐test. (E and F) The effect of intraperitoneal BCL6i and/or paclitaxel treatment (started day 18 postcell injection and ended on day 42) on MDA‐MB‐231 tumors ( n = 12) was assessed by measuring tumor volumes (E) and final tumor weights (F). Error bars represent standard error of the mean. (E) Tumor growth was modeled using simple linear regression and the slopes of the lines compared. The slopes are significantly different from each other ( P value = 0.0031). (F) Significance was determined using one‐way ANOVA followed by Tukey’s post‐test. (A to F) P values are indicated as follows: < 0.05 =*, < 0.01 =**, and < 0.001 =***. [Colour figure can be viewed at wileyonlinelibrary.com ]](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_3778/pmc08333778/pmc08333778__MOL2-15-2046-g004.jpg)